Full Generic Medicine Info
Dosage/Direction for Use

Pain and inflammation associated with musculoskeletal and joint disorders
Adult: 900 mg/day, either by 450 mg in the morning and evening or 300 mg in the morning and 600 mg in the evening.
Should be taken with food. Take w/ or immediately after meals.
Hypersensitivity to fenbufen or other NSAIDs. Lactation.
Special Precautions
Patient w/ gastric ulcer, cardiac disorders. Renal or hepatic impairment. Pregnancy. Patient Counselling This drug may cause blurred vision, if affected, do not drive or operate machinery.
Adverse Reactions
Nervous: Depression, dizziness, headache, numbness. GI: Anorexia, vomiting, abdominal pain, heartburn, diarrhoea, black stool, constipation, dry/sore mouth. Resp: Wheezing, dyspnoea. Ophthalmologic: Visual disturbance. Otic:D> Tinnitus. Dermatologic: Rash, toxic epidermal necrolysis, oedema, photosensitivity. Others: Fatigue.
Potentially Fatal: Erythema multiforme, Stevens-Johnson syndrome.
Drug Interactions
Decreased serum concentration w/ aspirin. Risk of convulsions when given w/ quinolones (e.g. enoxacin, ofloxacin). May enhance the anticoagulant effect of coumarins.
Fenbufen is a propionic acid derivative which prevents the synthesis of prostaglandins by inhibiting cyclooxygenase.
Absorption: Absorbed from the GI tract. Time to peak plasma concentration: Approx 70 min.
Distribution: Enters breast milk (small amounts). Plasma protein binding: >99%.
Metabolism: Metabolised in the liver to active metabolites, biphenylacetic acid and 4-hydroxy-biphenylbutyric acid.
Excretion: Via urine (mainly as conjugates). Plasma half-life: Approx 10-17 hr.
Oral: Store below 25°C.
ATC Classification
M01AE05 - fenbufen ; Belongs to the class of propionic acid derivatives of non-steroidal antiinflammatory and antirheumatic products.
Disclaimer: This information is independently developed by CIMS based on fenbufen from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in